Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-236 plus chemotherapy in advanced TNBC
NCT07108309Phase 2Recruiting
- Sponsor
- BIOCAD
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Countries
- 2
01
Overview
A Phase 2 trial of BCD-236 in triple-negative breast cancer (TNBC), sponsored by BIOCAD. Started Jul 2024; status: recruiting.
02
Drugs
BCD-236
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07108309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108309.